Researchers Show Novel Device Improves Blood Sugar Control in Hyperinsulinism Patients Whose Pancreas Has Been Removed

Researchers at Children’s Hospital of Philadelphia (CHOP) have demonstrated that an experimental device can improve blood sugar control in patients who developed diabetes after their pancreas was removed to treat their hyperinsulinism, a genetic disease in which the pancreas produces too much insulin. Using a combination of continuous glucose monitoring, two hormone pumps, and an algorithm, the device, known as the bihormonal bionic pancreas (BHBP) and developed by researchers at Boston University, helped HI patients with diabetes maintain stable glucose levels over the study period.

Tubeless automated insulin delivery system improves blood glucose outcomes

People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy. Results from an industry-sponsored study of the latest Omnipod, the first tubeless, wearable insulin pump, will be presented at ENDO 2021, the Endocrine Society’s annual meeting.

Youth with Diabetes Who are Involved in the Decision to Start Continuous Glucose Monitoring are More Likely to Continue Using It

In a new study published in Diabetes Care, researchers at Children’s Hospital of Philadelphia (CHOP) have found that youth who are involved with the decision to start CGM are more likely to continue using the monitoring technology more than two months after starting. The findings suggest that children and adolescents who do not have a role in the decision are less likely to be satisfied with the device and use the device consistently.

Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes

Fewer than one in five adolescents and young adults with type 1 diabetes are successful in achieving the recommended 2019 A1C goal of below 7.5%, and the overwhelming majority fail to achieve the 2020 target of less than 7%. But young people who use continuous glucose monitoring (CGM) devices can significantly improve their overall blood glucose control, without increasing severe low or high glucose levels, according to findings from a 6-month, multi-center clinical trial. And both severe hypoglycemia (low glucose) and hyperglycemia (high glucose) can lead to emergency care and hospitalization.

Medtronic MiniMed 670G insulin pump allows “excellent” blood glucose control

Patients with type 1 diabetes who use Medtronic’s MiniMedTM 670G insulin pump system are able to maintain blood glucose levels in the targeted range over 71% of the time, according to a study that analyzed some 6 million days of real-world data. Results of the industry-supported study were accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and will be published in a special supplemental issue of the Journal of the Endocrine Society.

People with type 1 diabetes still struggle with blood sugar control despite continuous glucose monitoring (CGM)

Some continuous glucose monitoring (CGM) alarm features and settings may achieve better blood sugar control for people with type 1 diabetes, according to a study published in the Journal of the Endocrine Society.